Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14782115 | 0.73 | PDK2 (0.38) | PDK2EGFRERBB2 | |
| SCHEMBL18926392 | 0.69 | CA2 (0.57) | ALDH1A1SMN1; SMN2LMNACA2POLB | |
| SCHEMBL5857102 | 0.69 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2LMNATNFRSF1ACA2 | |
| SCHEMBL25841356 | 0.69 | PGR (0.41) | ALDH1A1SMN1; SMN2KDM4ELMNAMDM2 | |
| SCHEMBL27724351 | 0.68 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2KDM4ELMNAMDM2 | |
| SCHEMBL15853193 | 0.68 | PDK2 (0.39) | PDK2PGR | |
| SCHEMBL1627404 | 0.68 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2PDK2CA2POLB | |
| SCHEMBL24122896 | 0.67 | NQO2 (0.37) | ALDH1A1SMN1; SMN2KDM4EPDK2PGR | |
| SCHEMBL18926391 | 0.67 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2LMNACA2POLB | |
| SCHEMBL16766189 | 0.67 | PDK2 (0.45) | ALDH1A1SMN1; SMN2KDM4ELMNAMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232359-B2 | Process for preparing ethylene homopolymers or copolymers of ethylene with α-olefin by using the transition metal compound | SK INNOVATION CO., LTD. (KR) | 2012-07-31 | — | — | US | disclosed |
| US-20110319576-A1 | PROCESS FOR PREPARING ETHYLENE HOMOPOLYMERS OR COPOLYMERS OF ETHYLENE WITH ALPHA-OLEFIN BY USING THE TRANSITION METAL COMPOUND | SK ENERGY CO., LTD. (KR) | 2011-12-29 | — | — | US | disclosed |
| EP-2326654-A2 | TRANSITION METAL CATALYTIC SYSTEMS AND METHODS FOR PREPARING ETHYLENE HOMOPOLYMERS OR COPOLYMERS OF ETHYLENE AND - OLEFINS USING THE SAME. | SK Energy Co., Ltd. (KR) | 2011-06-01 | — | — | EP | disclosed |
| US-20110098426-A1 | TRANSITION METAL CATALYTIC SYSTEMS AND METHODS FOR PREPARING ETHYLENE HOMOPOLYMERS OR COPOLYMERS OF THE ETHYLENE AND a-OLEFINS USING THE SAME | SK ENERGY CO., LTD. (KR) | 2011-04-28 | — | — | US | disclosed |
| US-7928173-B2 | Transition metal catalytic systems and methods for preparing ethylene homopolymers or copolymers of ethylene and α-olefins using the same | SK ENERGY CO., LTD. (KR) | 2011-04-19 | — | — | US | disclosed |
| US-20100081776-A1 | TRANSITION METAL CATALYTIC SYSTEMS AND METHODS FOR PREPARING ETHYLENE HOMOPOLYMERS OR COPOLYMERS OF ETHYLENE AND a-OLEFINS USING THE SAME | SABIC SK NEXLENE COMPANY PTE. LTD. (SG) | 2010-04-01 | — | — | US | disclosed |
| WO-2010036025-A2 | TRANSITION METAL CATALYTIC SYSTEMS AND METHODS FOR PREPARING ETHYLENE HOMOPOLYMERS OR COPOLYMERS OF ETHYLENE AND α- OLEFINS USING THE SAME. | SK ENERGY CO., LTD. (KR) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081776-A1 | TRANSITION METAL CATALYTIC SYSTEMS AND METHODS FOR PREPARING ETHYLENE HOMOPOLYMERS OR COPOLYMERS OF ETHYLENE AND a-OLEFINS USING THE SAME | ESR1, AOC3, PPOX | ALDH1A1 1685/4885SMN1; SMN2 1853/4885KDM4E 934/4885 |
| US-20110098426-A1 | TRANSITION METAL CATALYTIC SYSTEMS AND METHODS FOR PREPARING ETHYLENE HOMOPOLYMERS OR COPOLYMERS OF THE ETHYLENE AND a-OLEFINS USING THE SAME | ESR1, AOC3, AOC2 | ALDH1A1 1883/4885SMN1; SMN2 1999/4885KDM4E 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.